



February 17, 2016

Revance Therapeutics to Release Fourth Quarter and Full Year 2015 Financial Results Wednesday, March 2, 2016

Conference Call Scheduled for Wednesday, March 2, 2016 at 4:30pm ET

NEWARK, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will release fourth quarter and full year 2015 financial results on Wednesday, March 2, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 39010301; or from the webcast link in the investor relations section of the Company's website at: www.revance.com.

A replay of the call will be available beginning March 2, 2016 at 4:30pm PT/7:30pm ET through midnight on March 3, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 39010301. The webcast will be available in the investor relations section on the Company's website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin drug products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001) and DaxibotulinumtoxinA RT002 for Injection (RT002), in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com.

"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Investor Contact

Revance Therapeutics

Jeanie Herbert

(714) 325-3584

jherbert@revance.com

Westwicke Partners

Leigh Salvo

(415) 513-1281

leigh.salvo@westwicke.com

Trade Media Contact

Nadine Tosk

(847) 920-9858

nadinepr@gmail.com

Source: Revance Therapeutics, Inc

News Provided by Acquire Media